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Masked hypertension is diagnosed if the office blood 
pressure reading is  not increased but the out-of-
office-blood pressure reading by either home blood 
pressure monitoring or by ambulatory blood pressure 
monitoring is increased (1-3). Patients being treated for 
hypertension who have a normal office blood pressure 
reading but an increased out-of-office-blood pressure 
reading by either home blood pressure monitoring or 
by ambulatory blood pressure monitoring should be 
diagnosed as having masked uncontrolled hypertension (1). 
The European Society of Hypertension diagnosed an 
increased office blood pressure if the blood pressure 
was 140/90 mm Hg or higher and an increased out-
of-office-blood pressure if the home blood pressure 
reading was 135/85 mmHg or higher, the daytime blood 
pressure reading measured by ambulatory blood pressure 
monitoring was 135/85 mmHg or higher, or the 24-hour 
ambulatory blood pressure reading was 130/80 mmHg 
or higher (1). On the basis of current data, I would diagnose 
hypertension if the office systolic blood pressure was 
130 mmHg or higher or if the office diastolic blood pressure 
was 80 mmHg or higher (4,5). 
Masked hypertension might be suspected in persons 
with an increased office blood pressure at some time, in 
young persons with normal or high normal office blood 
pressure who have left ventricular hypertrophy, in persons 
who have a family history of hypertension in both parents, 
in diabetics, in persons with multiple cardiovascular risk 
factors, and in obese individuals (1). Masked hypertension 
is estimated to occur in 10% to 30% of persons (1). Masked 
hypertension was diagnosed by ambulatory blood pressure 
monitoring in 14% of persons and by home blood pressure 
monitoring by 11% of persons (6). It may be reasonable 
to screen for masked hypertension with ambulatory 
blood pressure monitoring or with home blood pressure 
monitoring if the office systolic blood pressure is 120 to 
129 mmHg or if the office diastolic blood pressure is 75 to 
79 mmHg (6-10).
The prevalence of masked uncontrolled hypertension 
in 14,840 persons with treated hypertension in a Spanish 
registry was 31.1% (3). The prevalence of masked 
uncontrolled hypertension was higher in men, in persons 
with a borderline office blood pressure, and in smokers, 
diabetics, and obese persons (3). Of 5,007 persons with 
untreated hypertension, 8.1% had masked hypertension (6). 
Of 1,451 persons in this study with treated hypertension, 
16.0% had masked uncontrolled hypertension. At 
8.3-year median follow-up, cardiovascular events in those 
with untreated hypertension were increased 55% in persons 
with masked hypertension and 2.13 times in persons with 
sustained hypertension. Cardiovascular events in persons 
with treated hypertension were increased 76% in persons 
with masked hypertension and 40% in persons with 
uncontrolled hypertension (6).
Of 332 persons, 22% had masked hypertension (7). 
Left ventricular mass index, carotid maximal intima-
media thickness, and urinary albumin level were higher 
in persons with masked hypertension than in persons 
with controlled hypertension and similar to those with 
sustained hypertension (7). A meta-analysis of seven studies 
including 11,502 persons, mean age 63 years, showed at 
8.0-year follow-up that compared to normotensive persons, 
persons with masked hypertension had a 2.0 times increase 
in first cardiovascular events, and persons with sustained 
hypertension had a 2.28 times increase in first cardiovascular 
events (8). 
A meta-analysis of eight studies including 7,964 persons 
showed that compared to normotensive persons, persons 
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with masked hypertension had at follow-up a 2.09 times 
increase in cardiovascular events, and persons with sustained 
hypertension had a 2.59 times increase in cardiovascular 
events (9). In 8,237 untreated persons, mean age 50.7 years, 
in 12 population studies, the prevalence of masked 
hypertension ranged from 9.7% to 19.6% (10). At follow-
up, compared to normotensive persons, persons with 
masked hypertension had a 1.76 to 2.03 times increase in 
cardiovascular events (10).
Of 1,332 Japanese persons,  16.6% had masked 
hypertension (11). At 10-year follow-up, compared to 
normotensive persons, persons with masked hypertension 
had a 1.88 times increased risk of cardiovascular disease 
mortality, a 2.17 times increased risk of stroke, and a 
2.13 times increase in risk of cardiovascular disease 
mortality and stroke (11). Compared to normotensive 
persons, persons with sustained hypertension had a 
1.94 times increased risk of cardiovascular disease 
mortality, a 2.83 times increased risk of stroke, and a 
2.26 times increase in risk of cardiovascular disease 
mortality and stroke (11). Of 3,027 persons, mean age 
47 years (50% blacks), in the Dallas Heart Study, 17.8% 
had masked hypertension (12). Persons with masked 
hypertension had increased aortic pulsed wave velocity, 
cystatin C, and urinary albumin-to creatinine ratio. At 
9.0-year median follow-up, after adjusting for traditional 
cardiovascular risk factors, compared with normotensive 
persons with masked hypertension had a 2.03 times 
increased risk of cardiovascular events, and persons with 
sustained hypertension had a 3.12 times increased risk of 
cardiovascular events (12). 
In 972 blacks, mean age 60 years, in the Jackson Heart 
Study, masked hypertension was present in 25.9% of 
persons and in 34.4% of persons with a normal clinic blood 
pressure (13). Male gender, smoking, diabetes mellitus, 
and use of antihypertensive drugs were independent 
determinants of masked hypertension. Common carotid 
artery intima-media thickness, left ventricular mass index, 
and the urinary albumin to creatinine excretion ratio were 
higher in persons with masked hypertension than in persons 
with normal blood pressure and similar in persons with 
masked hypertension and with sustained hypertension (13). 
Fewer modifiable cardiovascular risk factors measured 
by the American Heart Association Life’s Simple 7 was 
associated with a lower prevalence of masked hypertension 
in the Jackson Heart Study (14). In 644 participants in the 
Jackson Heart Study, the 10-year predicted atherosclerotic 
cardiovascular disease (ASCVD) risk was increased by 
masked hypertension 1.36 times by the pooled cohort risk 
equation if the ASCVD risk was 5% to 7.4%, 1.62 times if 
the ASCVD risk was 7.5% to 9.9%, and 1.91 times if the 
ASCVD risk was ≥10% (15).
Of 5,636 Canadian persons with hypertension treated in 
a primary care setting, 19.6% and 36.8% of persons with 
controlled office blood pressure had masked uncontrolled 
hypertension (16). Diabetes mellitus, older age, male gender, 
obesity, and higher office systolic blood pressure were 
associated with masked uncontrolled hypertension (16). 
Of 803 persons, mean age 60 years, with treated and 
controlled office blood pressure, 32.1% had masked 
uncontrolled hypertension (17). Masked uncontrolled 
hypertension was due to increased nocturnal blood pressure 
in 22.3% of persons and to poor daytime blood pressure 
increase in 10.1% of persons. Masked uncontrolled 
hypertension was associated with male gender, longer 
duration of hypertension, obesity, smoking, and diabetes 
mellitus (17). Using data from 9,316 persons in the National 
Health and Nutrition Examination Survey 2005–2010, the 
estimated prevalence of masked hypertension in the United 
States was 12.3% of adults (18). Masked hypertension was 
higher in older persons, men, diabetics, and those with 
prehypertension (18).
In 813 participants, mean age 45 years, without treated 
hypertension in the Masked Hypertension Study, 15.2% 
had masked hypertension (19). Echocardiographic left 
ventricular mass index was higher in persons with masked 
hypertension and in persons with prehypertension (19). In 
652 Swiss persons, mean age 48 years, masked hypertension 
was present in 15.8% of persons (20). Masked hypertension 
was associated with age (odds ratio =1.02), high-normal 
office blood pressure (odds ratio =6.68), and with obesity 
(odds ratio =3.63) (20). In 588 Chinese patients with non-
dialysis chronic kidney disease, mean age 43 years, 20.6% 
of patients had masked hypertension (21). At 35-month 
median follow-up, masked hypertension increased all-cause 
mortality 8.88 times, renal events 3.70 times, and major 
adverse cardiac and cerebrovascular events 8.66 times (21).
Nocturnal hypertension and non-dipping may be early 
markers of masked hypertension (22). Twenty-four hour 
ambulatory monitoring is the gold standard for diagnosing 
masked hypertension. Almost one-third of treated patients 
with masked hypertension have masked uncontrolled 
hypertension (22). There are scarce data on how to treat 
masked hypertension (23). One approach to treating masked 
hypertension would be to treat 24-hour ambulatory blood 
pressure (23). I would also aggressively treat modifiable 
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risk factors for masked hypertension. Although I would 
treat masked hypertension because of its association with 
increased cardiovascular and cerebrovascular events and 
mortality, we do not have clinical trial data demonstrating 
that treating masked hypertension will reduce cardiovascular 
and cerebrovascular events and mortality. Since masked 
hypertension may be a prognostic marker of adverse 
cardiovascular and cerebrovascular events and mortality, 
clinical trials need to be performed to investigate whether 
masked hypertension should be treated with antihypertensive 
drug therapy. 
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